Opiant Pharmaceuticals (OPNT) 10-Q 9 Dec 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Oct. 31, 2014	Dec. 05, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Lightlake Therapeutics Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--07-31	'
Amendment Flag	'false	'
Entity Central Index Key	'0001385508	'
Entity Filer Category	'Smaller Reporting Company	'
Document Period End Date	31-Oct-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Entity Common Stock, Shares Outstanding	'	182,010,212

Balance_Sheets

Balance Sheets (USD $)	Oct. 31, 2014	Jul. 31, 2014
Current assets	'	'
Cash and cash equivalents	$1,147,636	$254,770
Prepaid expenses and other current assets	534,542	24,079
Total current assets	1,682,178	278,849
Other assets	'	'
Patents and patent applications (net of accumulated amortization of $5,986 at October 31, 2014 and $5,642 at July 31, 2014)	21,464	21,808
Total assets	1,703,642	300,657
Current liabilities	'	'
Accounts payable and accrued liabilities	71,750	200,604
Accrued salaries and wages	1,638,231	1,416,651
Due to related parties	350,000	350,000
Total current liabilities	2,059,981	1,967,255
Deferred revenue	3,278,344	1,411,470
Total liabilities	5,338,325	3,378,725
Stockholders' deficit	'	'
Common stock; par value $0.001; 200,000,000 shares authorized; 178,991,893 shares issued and outstanding at October 31, 2014 and 178,207,278 shares issued and outstanding at July 31, 2014	178,991	178,206
Additional paid-in capital	43,294,876	43,076,939
Accumulated deficit during the development stage	-47,108,550	-46,333,213
Total stockholders' deficit	-3,634,683	-3,078,068
Total liabilities and stockholders' deficit	$1,703,642	$300,657

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Oct. 31, 2014	Jul. 31, 2014
Balance Sheets [Abstract]	'	'
Patents and patent applications, accumulated amortization (in Dollars)	$5,986	$5,642
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, share authorized (in Shares)	200,000,000	200,000,000
Common stock, share issued (in Shares)	178,991,893	178,207,278
Common stock, shares outstanding (in Shares)	178,991,893	178,207,278

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Operating expenses	'	'
General and administrative	$708,013	$1,481,983
Research and development	52,101	57,590
Total operating expenses	760,114	1,539,573
Loss from operations	-760,114	-1,539,573
Other income (expense)	'	'
Interest expense	-8,212	-125,547
Change in derivative	'	-48,713
Loss on foreign exchange	-7,011	'
Total other income (expense)	-15,223	-174,260
Loss before provision for income taxes	-775,337	-1,713,833
Provision for income taxes	'	'
Net loss	($775,337)	($1,713,833)
Loss per common share:	'	'
Basic and diluted	$0	($0.01)
Weighted average common shares outstanding	'	'
Basic and diluted	178,836,694	166,210,611

Statement_of_Stockholders_Defi

Statement of Stockholders' Deficit (USD $)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Deficit During the Development Stage [Member]
Balance at Jul. 31, 2014	($3,078,068)	$178,206	$43,076,939	($46,333,213)
Balance, shares at Jul. 31, 2014	178,207,278	178,207,278	'	'
Stock issued for services	44,723	785	43,938	'
Stock issued for services, shares	'	784,615	'	'
Stock based compensation from issuance of stock options	173,999	'	173,999	'
Net loss	-775,337	'	'	-775,337
Balance at Oct. 31, 2014	($3,634,683)	$178,991	$43,294,876	($47,108,550)
Balance, shares at Oct. 31, 2014	178,991,893	178,991,893	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Cash flows provided by (used in) operating activities	'	'
Net loss	($775,337)	($1,713,833)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'
Amortization	344	419
Issuance of common stock for services	44,723	110,668
Stock based compensation from issuance of options	173,999	1,080,201
Accreted interest on debt discounts	'	132,428
Change in derivative	'	48,713
Changes in assets and liabilities:	'	'
(Increase) decrease in prepaid expenses and other current assets	-510,463	8,500
Decrease in accounts payable	-128,854	-16,424
Increase in accrued salaries and wages	221,580	74,414
Net cash used by operating activities	-974,008	-274,914
Cash flows provided by (used in) investing activities	'	'
Cash flows provided by (used in) financing activities	'	'
Borrowings from related parties	'	'
Borrowings on convertible notes payable	'	'
Payments to related parties on notes payable	'	'
Investment received in exchange for royalty agreement	1,866,874	'
Issuance of common stock for cash	'	'
Net cash provided from financing activities	1,866,874	'
Net increase (decrease) in cash and cash equivalents	892,866	-274,914
Cash and cash equivalents, beginning of period	254,770	598,623
Cash and cash equivalents, end of period	1,147,636	323,709
Supplemental disclosure	'	'
Interest paid during the period	'	125,547
Taxes paid during the period	'	'
Non-Cash Transactions	'	'
Debt discounts attributable to derivative valuation	'	132,428
Settlement of derivative liability	'	8,820
Cashless exercise of warrants	'	1,524
Derivative liability	'	$337,413

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Oct. 31, 2014
Organization and Basis of Presentation [Abstract]	'
Organization and Basis of Presentation	'
		1	Organization and Basis of Presentation
	Lightlake Therapeutics Inc. (“Lightlake”, “we”, “our”, the “Company”) is a biopharmaceutical company focused on treatments for common addictions, including Binge Eating Disorder, and related disorders, including a treatment to reverse opioid overdoses.
	The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, these condensed financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These financial statements should be read in conjunction with the financial statements for the year ended July 31, 2014 and notes thereto and other pertinent information contained in the Form 10-K the Company has filed with the Securities and Exchange Commission (the “SEC”).
	The results of operations for the three months ended October 31, 2014 are not necessarily indicative of the results for the full fiscal year ending July 31, 2015.

Going_Concern

Going Concern	3 Months Ended
	Oct. 31, 2014
Going Concern [Abstract]	'
Going Concern	'
		2	Going Concern
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, the Company has incurred significant losses and is dependent on obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain the necessary funding it could cease operations as a new enterprise. This raises substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.
	The Company will need to seek additional funding. The Company currently does not have a specific plan of how the Company will obtain such funding; however, the Company anticipates that additional funding will be in the form of debt financing and/or equity financing from the sale of the Company's common stock and/or in the form of financing from the sale of interests in the Company's prospective products. At this time, the Company cannot provide investors with any assurance that the Company will be able to obtain sufficient funding to meet the Company's obligations over the next twelve months. The Company does not have any arrangements in place for any future financing and may seek to obtain additional short-term loans from its officers and directors to meet its short-term funding needs.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
		3	Summary of Significant Accounting Policies
	Use of estimates
	The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Prepaid supplies
	As of October 31, 2014, the Company has prepaid supplies of $493,360, which it will use in its clinical trials and the development of its products for testing purposes to meet the U.S. Food and Drug Administration requirements for approval of its treatment to reverse opioid overdoses. The Company expects to amortize these prepaid supplies to research and development costs as these are used over the course of its clinical studies and testing period.
	Deferred revenue
	Amounts from nonrefundable investments received in exchange for net profit interests in the Company's prospective products are recognized as deferred revenue and will be amortized on a straight-line basis over the contracted or estimated period of performance. The period of performance over which the revenues are recognized is typically the period over which the research and/or development is expected to occur or manufacturing services are expected to be provided. Such investments are contingently convertible to equity and as such, no amortization to revenue has been recorded. (see Note 5)
	Recently Issued Accounting Pronouncements
	The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Oct. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
		4	Related Party Transactions
	At October 31, and July 31, 2014, the Company had loans outstanding with its three directors (two of which are officers), in the total amount of $350,000.  The loans mature on January 6, 2015 and are subject to annual interest of 8.5%. In the event that at least one-third and one-sixth of the amount due plus interest is not repaid by September 30, 2014 and December 25, 2014, respectively, certain penalties will apply. As of October 1, 2014, the outstanding loan balances are subject to a penalty rate of 6% per annum due to non-payment of the required repayment amounts.

Deferred_Revenue

Deferred Revenue	3 Months Ended
	Oct. 31, 2014
Deferred Revenue [Abstract]	'
Deferred Revenue	'
	5	Deferred Revenue
	On July 22, 2014, the Company received a $3,000,000 commitment from a foundation, from which the Company has the right to make capital calls for the research, development, marketing, commercialization, and any other activities connected to the Company's treatment to reverse opioid overdoses, certain operating expenses, and any other purpose consistent with the goals of the foundation. On August 13 and September 8, 2014 the Company received investments of $422,344 and $444,530, respectively, from the foundation in exchange for a 0.844687% and a 0.888906% interest, respectively, in the Company's opioid overdose reversal treatment.
	On September 9, 2014, the Company entered into an agreement and subsequently received funding from an individual investor in the amount of $500,000 for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 0.98% interest in the Net Profit as related to the Company's treatment to reverse opioid overdoses. Net profit is defined as the pre-tax profit generated from the product after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. The investor also has rights with respect to its 0.98% interest if the treatment is sold or the Company is sold. Additionally, the Company may buyback interests from the investor within two and one half years or after two and a half years of the investment at a price of two times or three and a half times, respectively, the relevant investment amount represented by the interests to be bought back. If the product is not introduced to the market and not approved by the U.S. Food and Drug Administration or an equivalent body in Europe and not marketed within 24 months the investor will have a 60 day option to receive 5,000,000 shares of common stock in lieu of the interest in the product.
	On September 17, 2014, the Company entered into an agreement and subsequently received additional funding totaling $500,000 for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 1.0% interest in the Company's Binge Eating Disorder treatment product and pay the investor 1.0% of the net profit generated from this treatment in perpetuity. Net profit is defined as the pre-tax profit generated from the product after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. If the product is not approved by the U.S. Food and Drug Administration within 36 months the investor will have a sixty day option to receive 6,250,000 shares of common stock in lieu of the 1.0% interest in the product.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Oct. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
		6	Stockholders' Equity
	Common Stock
	On November 26, 2014, the Company amended its articles of incorporation to increase its authorized capital stock from 200,000,000 common shares to 1,000,000,000 common shares.
	In August 2014, the Company issued 784,615 shares to consultants for services rendered. The shares have a fair value of $44,723 based on stock prices at issuance dates.
	Stock Based Compensation
	As required by the Stock Compensation Topic, ASC 718, the Company measures and recognizes compensation expense for all share based payment awards made to the officers and directors based on estimated fair values. Stock based compensation expense recognized for the three months ended October 31, 2014 was $173,999.
	On August 2, 2014, the Company granted 3,000,000 stock options with an exercise price of $0.10 per share to a consultant for services rendered. These options have a term of 5 years and vested immediately. The Company has valued these options using the Black Scholes option pricing model which resulted in a fair market value of $173,999 which have been fully recognized as expense for the three months ended, October 31, 2014. The assumptions used in the valuation were as follows:
	Market value of stock on measurement date		$	0.058
	Risk-free interest rate			1.73	%
	Dividend yield			0	%
	Volatility factor			413	%
	Term			5.0 years
	Stock option activity for three months ended October 31, 2014 is presented in the table below:
			Number of			Weighted-		Weighted-		Aggregate
			Shares			average		average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Term (years)
	Outstanding at July 31, 2014			304,750,000			0.09		8.56	$	12,000
	Granted			3,000,000			0.1		5
	Forfeited/expired/cancelled			-			-		-
	Outstanding at October 31, 2014			307,750,000			0.09		8.27	$	-
	Exercisable at October 31, 2014			162,025,000			0.1		8.19	$	-
	Warrants
	Warrant activity for quarter ended October 31, 2014 is presented in the table below:
			Number of			Weighted-		Weighted-		Aggregate
			Shares			average		average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Term (years)
	Outstanding at July 31, 2014			125,475,239			0.2		4.33	$	-
	Granted			-					-
	Exercised			-					-
	Outstanding at October 31, 2014			125,475,239			0.2		4.33	$	-
	Exercisable at October 31, 2014			52,975,239			0.2		4.08	$	-

Subsequent_Events

Subsequent Events	3 Months Ended
	Oct. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
		7	Subsequent Events
	On October 31, 2014, the Company entered into an agreement and subsequently received funding from an individual investor in the amount of $500,000 for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 0.98% interest in the Net Profit as related to the Company's treatment to reverse opioid overdoses. Net profit is defined as the pre-tax profit generated from the product after the deduction of all expenses incurred by and payments made by the Company in connection with the product, including but not limited to an allocation of Company overhead. The investor also has rights with respect to its 0.98% interest if the treatment is sold or the Company is sold. Additionally, the Company may buyback the interest from the investor within two and one half years or after two and a half years but no later than four years of the investment at a price of two times or three and a half times, respectively, of the investment amount. If the product is not introduced to the market and not approved by the U.S. Food and Drug Administration or an equivalent body in Europe and not marketed within 24 months the investor will have a 60 day option to receive 5,000,000 shares of common stock in lieu of the interest in the product.
	On November 13, 2014, the Company made a capital call of $1,033,614 from the aforementioned foundation (see Note 5) in exchange for a 2.067228% interest in the Company's opioid overdose reversal treatment.
	On December 1, 2014, the Company and Aegis Therapeutics, LLC (“Aegis”), entered into a Material Transfer, Option and Research License Agreement (the “License Agreement”) that provides the Company with an exclusive royalty-free research license for a period of time to Aegis' proprietary delivery enhancement and stabilization agents, including Aegis' ProTek® and Intravail® technologies (collectively, the “Technology”) to enable the Company to conduct a feasibility study of opioid antagonists when used with the Technology. During this period of time, the Company may also evaluate its interest in having an exclusive license to the Technology for use with opioid antagonists to treat, diagnose, predict, detect or prevent any disease, disorder, state, condition or malady in humans (the “Possible License”). Aegis has granted the Company an exclusive option to obtain the Possible License for a certain period after the study is completed.
	In consideration of the license granted to the Company pursuant to the License Agreement, the Company is required to pay to Aegis a nonrefundable study fee.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Use of estimates	'
	Use of estimates
	The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Prepaid supplies	'
	Prepaid supplies
	As of October 31, 2014, the Company has prepaid supplies of $493,360, which it will use in its clinical trials and the development of its products for testing purposes to meet the U.S. Food and Drug Administration requirements for approval of its treatment to reverse opioid overdoses. The Company expects to amortize these prepaid supplies to research and development costs as these are used over the course of its clinical studies and testing period.
Deferred revenue	'
	Deferred revenue
	Amounts from nonrefundable investments received in exchange for net profit interests in the Company's prospective products are recognized as deferred revenue and will be amortized on a straight-line basis over the contracted or estimated period of performance. The period of performance over which the revenues are recognized is typically the period over which the research and/or development is expected to occur or manufacturing services are expected to be provided. Such investments are contingently convertible to equity and as such, no amortization to revenue has been recorded. (see Note 5)
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Oct. 31, 2014
Stockholders' Equity [Abstract]	'
Schedule of Assumptions Used in the Valuation	'
	Market value of stock on measurement date	$	0.058
	Risk-free interest rate		1.73	%
	Dividend yield		0	%
	Volatility factor		413	%
	Term		5.0 years
Schedule of Options and Warrants Outstanding	'
		Number of			Weighted-		Weighted-		Aggregate
		Shares			average		average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (years)
	Outstanding at July 31, 2014		304,750,000			0.09		8.56	$	12,000
	Granted		3,000,000			0.1		5
	Forfeited/expired/cancelled		-			-		-
	Outstanding at October 31, 2014		307,750,000			0.09		8.27	$	-
	Exercisable at October 31, 2014		162,025,000			0.1		8.19	$	-
		Number of			Weighted-		Weighted-		Aggregate
		Shares			average		average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (years)
	Outstanding at July 31, 2014		125,475,239			0.2		4.33	$	-
	Granted		-					-
	Exercised		-					-
	Outstanding at October 31, 2014		125,475,239			0.2		4.33	$	-
	Exercisable at October 31, 2014		52,975,239			0.2		4.08	$	-

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Prepaid supplies	$493,360

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Oct. 31, 2014	Jul. 31, 2014
Related Party Transaction [Line Items]	'	'
Due to related parties	$350,000	$350,000
Debt instrument, interest rate	8.50%	'
Penalty rate	6.00%	'

Deferred_Revenue_Details

Deferred Revenue (Details) (USD $)	0 Months Ended
	Sep. 08, 2014	Sep. 09, 2014	Aug. 13, 2014	Jul. 22, 2014	Sep. 17, 2013
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'
Proceeds from funding agreement	$444,530	$500,000	$422,344	'	$500,000
Interest in asset	0.89%	0.98%	0.84%	'	1.00%
Number of shares issuable	'	5,000,000	'	'	6,250,000
Deferred Revenue, Additions	'	'	'	$3,000,000	'

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock) (Details) (USD $)	1 Months Ended	3 Months Ended
	Aug. 31, 2014	Oct. 31, 2014	Nov. 26, 2014	Jul. 31, 2014
Stockholders' Equity [Abstract]	'	'	'	'
Common stock, share authorized (in Shares)	'	200,000,000	1,000,000,000	200,000,000
Stock issued for services, shares	784,615	'	'	'
Stock issued for services	$44,723	$44,723	'	'

Stockholders_Equity_Stock_Base

Stockholders' Equity (Stock Based Compensation) (Details) (USD $)	0 Months Ended	3 Months Ended
	Aug. 02, 2014	Oct. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	'	$173,999
Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options granted	3,000,000	3,000,000
Options granted, exercise price	$0.10	$0.10
Expiration period	'5 years	'
Market value of stock on measurement date	'	$0.06
Risk-free interest rate	'	1.73%
Dividend yield	'	0.00%
Volatility factor	'	413.00%
Term	'	'5 years
Stock Option [Member] | August 2 Option Grant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock based compensation expense	'	$173,999

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Outstanding Options and Warrants) (Details) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Aug. 02, 2014	Oct. 31, 2014	Jul. 31, 2014
WARRANTS [Member]	'	'	'
Number of Shares	'	'	'
Outstanding, beginning balance	125,475,239	125,475,239	'
Granted	'	'	'
Exercised	'	'	'
Outstanding, ending balance	'	125,475,239	125,475,239
Exercisable	'	52,975,239	'
Weighted- average Exercise Price	'	'	'
Outstanding	$0.20	$0.20	'
Granted	'	'	'
Exercised	'	'	'
Outstanding	'	$0.20	$0.20
Exercisable	'	$0.20	'
Weighted- average Remaining Contractual Term (years)	'	'	'
Outstanding	'	'4 years 3 months 29 days	'4 years 3 months 29 days
Exercisable	'	'4 years 29 days	'
Aggregate Intrinsic Value	'	'	'
Outstanding	'	'	'
Exercisable	'	'	'
OPTIONS [Member]	'	'	'
Number of Shares	'	'	'
Outstanding, beginning balance	304,750,000	304,750,000	'
Granted	3,000,000	3,000,000	'
Forfeited/expired/cancelled	'	'	'
Outstanding, ending balance	'	307,750,000	304,750,000
Exercisable	'	162,025,000	'
Weighted- average Exercise Price	'	'	'
Outstanding	$0.09	$0.09	'
Granted	$0.10	$0.10	'
Forfeited/expired/cancelled	'	'	'
Outstanding	'	$0.09	$0.09
Exercisable	'	$0.10	'
Weighted- average Remaining Contractual Term (years)	'	'	'
Granted	'	'5 years	'
Outstanding	'	'8 years 3 months 7 days	'8 years 6 months 22 days
Exercisable	'	'8 years 2 months 8 days	'
Aggregate Intrinsic Value	'	'	'
Outstanding	'	'	12,000
Exercisable	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended
	Sep. 08, 2014	Sep. 09, 2014	Aug. 13, 2014	Sep. 17, 2013	Nov. 13, 2014	Oct. 31, 2014
					Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'
Proceeds from funding agreement	$444,530	$500,000	$422,344	$500,000	$1,033,614	$500,000
Interest in asset	0.89%	0.98%	0.84%	1.00%	2.07%	98.00%
Number of shares issuable	'	5,000,000	'	6,250,000	'	5,000,000